DataLookout › Clinical Trial Tracker › CAR-T Pipeline

CAR-T Cell Therapy Clinical Trials — 2026 Pipeline Tracker

CAR-T has reshaped treatment for relapsed blood cancers and is now moving into autoimmune disease. Track all 285+ active CAR-T trials — hematologic malignancies, solid tumors, and the emerging autoimmune frontier — with daily alerts the moment new studies open or existing ones change.

Track Free CAR-T Trials
285+
Active CAR-T trials (2026)
184
Currently recruiting
11
Phase 3 pivotal programs
6
FDA-approved CAR-T therapies

Phase 3 CAR-T Trials — Active 2026

These pivotal programs will define how CAR-T moves into earlier lines of hematologic malignancy and into autoimmune disease through 2027–2028.

NCT ID Program / Regimen Sponsor Indication Phase
NCT04181827 JNJ-68284528 (ciltacabtagene autoleucel / Carvykti) vs standard Janssen Relapsed/refractory multiple myeloma (CARTITUDE-4) Phase 3
NCT04923893 VRd followed by Carvykti vs VRd alone (1L myeloma) Janssen Newly diagnosed multiple myeloma (CARTITUDE-6) Phase 3
NCT07391657 AZD0120 (dual BCMA/CD38 CAR-T) vs standard of care AstraZeneca Relapsed/refractory multiple myeloma Phase 3
NCT07335562 BMS-986353 (zolacaptogene iraleucel) vs investigator choice CAR-T Juno / Bristol Myers Squibb Relapsed/refractory large B-cell lymphoma Phase 3
NCT06193889 KYV-101 (anti-CD19 CAR-T) vs standard immunosuppression Kyverna Therapeutics Autoimmune disease (KYSA-6) Phase 3
NCT06799247 Descartes-08 (mRNA anti-CD19 CAR-T) vs placebo Cartesian Therapeutics Generalized myasthenia gravis Phase 3
NCT07188558 Ronde-cel (anti-CD19) vs investigator choice CD19 CAR-T Lyell Immunopharma Relapsed/refractory large B-cell lymphoma Phase 3
NCT07441291 CD19 CAR-T vs donor lymphocyte infusion (DLI) Peking University People's Hospital Post-HSCT MRD+ Ph- ALL Phase 3
NCT06652633 GLPG5101 (anti-CD19 allogeneic) long-term follow-up Galapagos NV B-cell non-Hodgkin lymphoma Phase 3

Track CAR-T trials in your indication

Set up a watchlist on DataLookout and receive email alerts when new CAR-T studies open, reach Phase 3, or report results. Free 14-day trial — no credit card required.

Set Up CAR-T Watchlist

CAR-T Target Antigens — 2026 Landscape

The approved CAR-T drugs target two antigens. The pipeline targets many more, with particular interest in dual-antigen constructs (to reduce antigen-loss relapse) and B-cell antigens driving autoimmune disease.

CD19
Kymriah, Yescarta, Breyanzi, Tecartus — plus autoimmune programs (Kyverna, Cartesian, Lyell). The dominant B-cell malignancy and autoimmune target.
BCMA
Carvykti (Janssen), Abecma (BMS). Multiple myeloma's primary CAR-T target. AZD0120 adds CD38 co-targeting to address antigen escape.
GPRC5D
Talquetamab, plus multiple CAR-T programs in myeloma. An alternative BCMA-escape target — trials exploring BCMA+GPRC5D dual constructs.
CD22
Combination CD19/CD22 dual CAR programs in ALL and DLBCL — designed to prevent single-antigen loss relapse that limits CD19-only CAR-T.
B7-H3
Solid tumor target. Multiple early-phase programs in glioblastoma, neuroblastoma, prostate, lung, and colorectal cancers. Phase 1/2 stage.
GD2
Pediatric solid tumors: neuroblastoma, osteosarcoma, DIPG. Academic-led Phase 1/2 programs at St. Jude, MD Anderson, City of Hope.

Where CAR-T Is Heading: Key 2026 Trends

1. Autoimmune Disease — The Biggest Expansion Opportunity

Multiple early studies have demonstrated that a single CD19 CAR-T infusion can induce sustained, drug-free remission in treatment-refractory SLE, myasthenia gravis, and inflammatory myopathies. The mechanism: deep B-cell depletion followed by immune reset as naive B cells repopulate. Kyverna Therapeutics (KYSA-6, Phase 3) and Cartesian Therapeutics (Descartes-08, Phase 3 in MG) are the furthest along in pivotal trials. If Phase 3 data confirm Phase 1/2 results, CAR-T could enter the autoimmune market — a far larger commercial opportunity than hematologic malignancies.

2. Allogeneic ("Off-the-Shelf") CAR-T

All six approved CAR-T therapies are autologous — made from the patient's own T cells, requiring 3–6 weeks of manufacturing and failing when T-cell quality is poor. Allogeneic CAR-T uses healthy donor T cells edited to prevent graft-versus-host disease, enabling immediate availability and potentially lower cost. Galapagos (GLPG5101), Allogene, and multiple academic programs are in Phase 2/3. Regulatory acceptance of allogeneic T-cell products remains the key open question.

3. Earlier Lines in Hematology

Carvykti and Abecma were initially approved for 4th-line+ multiple myeloma. CARTITUDE-4 data (JNJ-68284528) showed superiority versus standard of care in 2nd-line myeloma. Phase 3 programs are now enrolling newly diagnosed myeloma (1st-line). The commercial prize for 1L myeloma CAR-T is several billion dollars per year in the US alone.

4. Solid Tumors — Still Challenging

CAR-T in solid tumors remains Phase 1/2. The immunosuppressive tumor microenvironment, poor T-cell trafficking, and antigen heterogeneity continue to limit activity. B7-H3, GD2, and mesothelin are the most-advanced solid tumor targets. Some early signals in glioblastoma and neuroblastoma, but no regulatory approvals yet.

Approved CAR-T Therapies — 2026 Reference

Drug (Generic) Brand Target Sponsor Approved Indication
Tisagenlecleucel Kymriah CD19 Novartis Pediatric ALL; relapsed/refractory DLBCL and FL
Axicabtagene ciloleucel Yescarta CD19 Gilead / Kite Relapsed/refractory large B-cell lymphoma and FL
Brexucabtagene autoleucel Tecartus CD19 Kite / Gilead Relapsed/refractory mantle cell lymphoma; ALL
Lisocabtagene maraleucel Breyanzi CD19 Bristol Myers Squibb Relapsed/refractory large B-cell lymphoma (2L+)
Ciltacabtagene autoleucel Carvykti BCMA Janssen / Legend Relapsed/refractory multiple myeloma (2L+)
Idecabtagene vicleucel Abecma BCMA Bristol Myers Squibb Relapsed/refractory multiple myeloma (4L+)

Frequently Asked Questions

What is CAR-T cell therapy?
CAR-T (chimeric antigen receptor T-cell) therapy is a form of adoptive cell therapy in which a patient's own T cells are collected, genetically engineered to express a synthetic receptor targeting a tumor antigen, expanded in the lab, and reinfused to attack cancer. The chimeric antigen receptor combines an extracellular antigen-binding domain with intracellular T-cell signaling domains. Most approved CAR-Ts are autologous (patient-derived); next-generation programs aim for allogeneic (off-the-shelf) manufacturing to eliminate the 3–6 week vein-to-vein time.
What CAR-T therapies are currently approved?
Six CAR-T therapies have received FDA approval: Kymriah (tisagenlecleucel, Novartis) — CD19, ALL and DLBCL; Yescarta (axicabtagene ciloleucel, Gilead/Kite) — CD19, large B-cell lymphoma; Tecartus (brexucabtagene, Kite) — CD19, mantle cell lymphoma and ALL; Breyanzi (lisocabtagene maraleucel, BMS) — CD19, large B-cell lymphoma; Carvykti (ciltacabtagene autoleucel, Janssen) — BCMA, multiple myeloma; Abecma (idecabtagene vicleucel, BMS) — BCMA, multiple myeloma. All six approved therapies target blood cancers; solid tumor CAR-T remains in early development.
What are the most important CAR-T clinical trials in 2026?
The highest-impact Phase 3 CAR-T programs include: CARTITUDE-4/6 (Janssen, Carvykti in earlier myeloma lines), AZD0120 (AstraZeneca, dual BCMA/CD38 in myeloma), KYSA-6 (Kyverna, CD19 in autoimmune disease), Descartes-08 (Cartesian, mRNA CAR-T in myasthenia gravis), and BMS-986353 (Juno/BMS, next-gen CD19 CAR-T in DLBCL). The autoimmune programs represent the most novel frontier — potential to expand the CAR-T market beyond blood cancers.
Can CAR-T cell therapy treat autoimmune diseases?
Yes — CD19-targeting CAR-T is being evaluated in SLE, myasthenia gravis, inflammatory myopathies, systemic sclerosis, and anti-NMDA receptor encephalitis. Early data showed sustained remissions in SLE patients after a single infusion, with some patients achieving drug-free remission for 2+ years. Multiple Phase 3 trials are now underway, with Kyverna Therapeutics and Cartesian Therapeutics leading. If Phase 3 data confirm earlier results, CAR-T could enter the autoimmune market — a larger commercial opportunity than blood cancers.
How can I track new CAR-T clinical trials?
DataLookout monitors ClinicalTrials.gov daily and sends email alerts for new and updated CAR-T trials filtered to your criteria. Track by target antigen (CD19, BCMA, GPRC5D), by sponsor, by disease, or by phase. Free accounts receive weekly summaries; Starter and Pro plans unlock daily digests and multiple watchlists. Start tracking at dashboard.datalookout.com.

Related Clinical Trial Trackers